HHS and FDA Advance Interim Policy for Peptide Compounding

The U.S. Department of Health and Human Services (HHS) and the FDA have submitted an interim policy on compounding certain peptides to the Office of Management and Budget for regulatory review. This action is crucial for wellness providers, as no peptides are currently on the FDA's official list for compounding under Section 503A, despite advisory committee recommendations earlier this year. The policy aims to provide clarity on access while formal rulemaking is pending.